SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Unichem Laboratories soars on getting tentative approval for Tadalafil Tablets

12 Dec 2018 Evaluate

Unichem Laboratories is currently trading at Rs. 194.80, up by 3.55 points or 1.86% from its previous closing of Rs. 191.25 on the BSE.

The scrip opened at Rs. 198.05 and has touched a high and low of Rs. 198.05 and Rs. 194.20 respectively. So far 12760 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 382.00 on 08-Jan-2018 and a 52 week low of Rs. 182.00 on 11-Oct-2018.

Last one week high and low of the scrip stood at Rs. 199.70 and Rs. 188.75 respectively. The current market cap of the company is Rs. 1367.55 crore.

The promoters holding in the company stood at 50.67%, while Institutions and Non-Institutions held 10.22% and 39.11% respectively.

Unichem Laboratories has received Tentative Approval for its Abbreviated New Drug Application (ANDA), Tadalafil Tablets, 2.5 mg, 5 mg 10 mg and 20 mg from the United States Food and Drug Administration (USFDA) for a generic version of ELI LILLY's Cialis, 2.5 mg, 5 mg, 10 mg and 20 mg.

The company's Tadalafil Tablets are indicated for the treatment of erectile dysfunction (ED) and treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) and the treatment of ED and the signs and symptoms of BPH (ED/BPH).

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.


Unichem Laboratories Share Price

473.30 9.90 (2.14%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: